Lake Street Capital Cuts Cellebrite DI (NASDAQ:CLBT) Price Target to $22.00

Key Points

• Lake Street Capital has lowered its price objective for Cellebrite DI (NASDAQ:CLBT) from $24.00 to $22.00, while maintaining a "buy" rating on the stock.
• Recent earnings data indicated that Cellebrite DI reported $0.12 EPS for the quarter, surpassing consensus estimates of $0.11 EPS, alongside an 18.4% year-over-year revenue growth.
• Institutional investors own approximately 45.88% of Cellebrite DI's stock, highlighting significant interest from hedge funds and investment firms in the company.

Cellebrite DI (NASDAQ:CLBT - Free Report) had its price objective reduced by Lake Street Capital from $24.00 to $22.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also recently commented on CLBT. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. JPMorgan Chase & Co. dropped their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Finally, Wall Street Zen cut shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cellebrite DI presently has an average rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Trading Down 2.0%

Shares of Cellebrite DI stock traded down $0.32 during trading on Friday, reaching $15.48. The company's stock had a trading volume of 1,678,504 shares, compared to its average volume of 1,674,255. The company has a 50-day moving average price of $14.95 and a two-hundred day moving average price of $17.65. The firm has a market cap of $3.71 billion, a PE ratio of -20.37, a P/E/G ratio of 3.20 and a beta of 1.27. Cellebrite DI has a fifty-two week low of $13.10 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company's quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Several institutional investors have recently made changes to their positions in the stock. Axon Enterprise Inc. purchased a new stake in shares of Cellebrite DI during the 4th quarter worth $198,270,000. Voss Capital LP boosted its position in shares of Cellebrite DI by 34.0% during the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company's stock worth $82,400,000 after purchasing an additional 1,306,398 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Cellebrite DI by 17.1% during the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company's stock worth $62,608,000 after purchasing an additional 570,000 shares in the last quarter. Invesco Ltd. boosted its position in shares of Cellebrite DI by 6.4% during the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company's stock worth $56,089,000 after purchasing an additional 209,473 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in shares of Cellebrite DI during the 1st quarter worth $60,939,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.